Metaplastic Breast Carcinomas Are Basal-Like Breast Cancers: A Genomic Profiling Analysis
B Weigelt, B Kreike, JS Reis-Filho. Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley; The Netherlands Cancer Institute, Amsterdam, Netherlands; ICR, London, United Kingdom
Background: Metaplastic breast carcinomas (MBCs) comprise a group of aggressive and chemotherapy resistant cancers characterised by neoplastic cells displaying differentiation towards squamous epithelium or mesenchymal elements. Previous histopathological and immunohistochemical analysis of MBCs suggested that these cancers would have a basal-like profile.
Design: We investigated the molecular subtype of 20 MBCs using microarray-based expression profiling data. These expression data were compared to those of 79 invasive ductal carcinomas (IDCs) of basal-like phenotype by unsupervised hierarchical clustering, supervised analysis and gene pathway analysis.
Results: We demonstrate that 95% of all MBCs are of basal-like molecular subtype. Furthermore, unsupervised hierarchical clustering analysis and pathway analysis of the profiles of MBCs revealed that MBCs are part of the spectrum of basal-like breast cancers. Significance analysis of microarrays (SAM) identified 1385 transcripts differentially expressed between MBCs and IDCs of basal-like phenotype. Pathway analysis using these genes revealed that DNA repair pathways, including BRCA1 pathway, PTEN, a gene whose loss of function is associated with resistance to chemotherapy, and TOP2A, the molecular target of anthracyclines, are significantly downregulated in MBCs compared to basal-like IDCs. These findings may at least in part explain the reported poor responses to chemotherapy of MBCs. Furthermore, MBCs showed significantly higher expression of genes related to myoepithelial differentiation and epithelial to mesenchymal transition.
Conclusions: Our results demonstrate that MBCs are part of the spectrum of basal-like breast carcinomas and display a myoepithelial and EMT-like molecular make-up. The reported poorer response to chemotherapeutic agents in patients with MBCs may stem from downregulated DNA damage response pathways, PTEN and TOP2A.
Tuesday, March 10, 2009 1:00 PM
Poster Session IV # 43, Tuesday Afternoon